{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:17:36Z","timestamp":1791080256259,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":4362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/labinvest.2010.148","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T10:31:46Z","timestamp":1286188306000},"page":"241-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis"],"prefix":"10.1016","volume":"91","author":[{"given":"Martin","family":"Hennenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"Kohistani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Nischalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Granzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Sauerbruch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/labinvest.2010.148_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.22687","article-title":"Therapy for portal hypertension: what is our pipeline?","volume":"49","author":"Shah","year":"2009","journal-title":"Hepatology"},{"key":"10.1038\/labinvest.2010.148_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/gut.2005.081059","article-title":"Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis","volume":"55","author":"Zhou","year":"2006","journal-title":"Gut"},{"key":"10.1038\/labinvest.2010.148_bib3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers in portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"10.1038\/labinvest.2010.148_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.50.4.571","article-title":"Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension","volume":"50","author":"Reynaert","year":"2002","journal-title":"Gut"},{"key":"10.1038\/labinvest.2010.148_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1038\/labinvest.2010.148_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.21564","article-title":"Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?","volume":"45","author":"Lee","year":"2007","journal-title":"Hepatology"},{"key":"10.1038\/labinvest.2010.148_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/labinvest.2010.148_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Hennenberg","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1038\/labinvest.2010.148_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2008","journal-title":"Hepatology"},{"key":"10.1038\/labinvest.2010.148_bib10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.23222","article-title":"Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis","volume":"50","author":"Trebicka","year":"2009","journal-title":"Hepatology"},{"key":"10.1038\/labinvest.2010.148_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1634\/theoncologist.2008-0281","article-title":"Commentary: sorafenib use in patients with advanced hepatocellular carcinoma and underlying child-pugh B cirrhosis\u2014evidence and controversy","volume":"14","author":"Zhu","year":"2009","journal-title":"Oncologist"},{"key":"10.1038\/labinvest.2010.148_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","article-title":"Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis","volume":"14","author":"Pinter","year":"2009","journal-title":"Oncologist"},{"key":"10.1038\/labinvest.2010.148_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"10.1038\/labinvest.2010.148_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1038\/labinvest.2010.148_bib15","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Schramm","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/labinvest.2010.148_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Llanos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/labinvest.2010.148_bib17","first-page":"423","article-title":"Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration","volume":"152","author":"Marra","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1038\/labinvest.2010.148_bib18","doi-asserted-by":"crossref","first-page":"G765","DOI":"10.1152\/ajpgi.00308.2005","article-title":"Secretion of MCP-1\/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts","volume":"290","author":"Kruglov","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1038\/labinvest.2010.148_bib19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis","volume":"43","author":"W\u00f6rns","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1038\/labinvest.2010.148_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MEG.0b013e328333df23","article-title":"Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma","volume":"22","author":"Peck-Radosavljevic","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1038\/labinvest.2010.148_bib21","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1158\/1535-7163.MCT-06-0595","article-title":"Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice","volume":"6","author":"Kim","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/labinvest.2010.148_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Reiberger","year":"2009","journal-title":"J Hepatol"},{"key":"10.1038\/labinvest.2010.148_bib23","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/labinvest2010148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest2010148","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002368372202801X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002368372202801X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/labinvest2010148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:52:55Z","timestamp":1758397975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002368372202801X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S002368372202801X"],"URL":"https:\/\/doi.org\/10.1038\/labinvest.2010.148","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/labinvest.2010.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}